Availability of Serum Samples from HALT-C Trial and Research Support for Validation of Hepatocellular Carcinoma (HCC) Biomarkers

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), in collaboration with National Cancer Institute (NCI), through its Early Detection Research Network (EDRN), announces the availability of serum samples and research funds for validation of biomarkers for hepatocellular carcinoma among study participants in the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis (HALT-C) trial. Applications will be accepted for sequential phase II and phase III biomarker validation studies as described in this document.
Version 5.1.0